Navigation Links
Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
Date:10/22/2013

Atlanta, Georgia (PRWEB) October 22, 2013

Jeevan BioSciences, Inc. (http://www.jeevanbiosciences.com) a start-up biotechnology company co-founded by Dr. Rodney Nash, PhD, a former Neuroscience Post-Doctoral Fellow at Emory University, today announces the commercial release of its first product Neuro – XTM Tissue Culture Media; the first 100% serum-free and xeno-free media product available on the market. Neuro-XTM is a proprietary patent pending chemically defined media specifically formulated for use in the growth of human cells and tissue without the need for serum or other animal products. The product was originally developed to support the growth of neuronal cells, but has been engineered to support the growth of multiple types of human cells including U87, HeLa, Neural progenitors, MCF7, Raji, A549, 143B, HS587T, PSCs, Cancer Stem Cells, Foreskin Fibroblasts, as well as MEF and 3T3 mouse cells. Researchers using Neuro-XTM are discovering that the product supports additional cell types on an almost weekly basis.

“It is well-known that serum is essentially a contaminant that significantly affects the ability to obtain reliable and reproducible results when it comes to cell culturing, and we knew that developing a serum-free and xeno-free media would solve this problem”, says Dr. Rodney Nash, CEO of Jeevan BioScience.

Neuro-XTM is a proprietary DMEM/F-12 base media that contains no animal-derived components or albumin, and efficiently grows all types of human cells and tissue including cancer cells, stem cells, neuronal cells, foreskin fibroblast, and muscle cells. The media also effectively grows mouse cells and other tissue as well. “We are excited about the possibilities when you consider the number of different cell types that Neuro-XTM supports”, continues Dr. Nash. “We constantly hear about additional cell types that the media supports from other researchers around the country that are using the media, and we encourage them to run new experiments and expand the possibilities of their research”.

“This media maintains stemness in neuronal progenitor cells,” says Dr. Jie Xu, Ph.D. a researcher at Georgia State University. “We have been able to successfully infect these cells with Sindbis virus and maintain neuronal progenitor cells using Neuro-XTM media, and now we intend to include this media as an important tool in our research initiatives”. Neuro-XTM media is also being used by cancer researchers across the country. “We are very impressed with Neuro-XTM in maintaining and differentiating patient glioma tumor-derived (primary cells) cancer stem cell,” says Carol Tucker-Burden a researcher at Emory University. “The Neuro-XTM media maintains the tumor-derived neurospheres similarly in comparison to our supplemented media without the need for us to be concerned with serum, which we consider to be a contaminant”.

Neuro-XTM is available at an introductory price of US$199.00 per 500ML bottle, and is distributed by World Wide Medical Products, Inc. (http://www.wwmponline.com), a laboratory products and services company located in Bristol Pennsylvania. “We are very impressed with the Neuro-XTM product and the team at Jeevan Biosciences”, says David Spaventa, Director of Sales & Strategic Alliances at World Wide Medical Products. “Prior to our relationship with Jeevan we had never distributed a media product, but decided to distribute Neuro-XTM given its unique quality as the only true serum-free and xeno-free media available on the market, and the significant growth potential for a product like this”. Free samples of Neuro-XTM media are available in units of 50mL and 100mL from World Wide Medical Products (1-866-889-9967).

Additional information about the Neuro-XTM product can be found on the Jeevan Biosciences website (http://www.jeevanbiosciences.com,) including product brochures and scientific papers that provide technical details about how the media is being used in scientific research and drug development.

About Jeevan Bio Sciences, Inc.
Jeevan Biosciences, Inc. is an Atlanta-based biotechnology company committed to the development of cellular models for cancer and neurologic disease research and drug testing. Through accurate cellular model systems, we strive to bridge the gap between research and medicine to improve the quality of life for patient populations who would benefit the most.

Read the full story at http://www.prweb.com/releases/jeevanbiosciences/neurox/prweb11252250.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
2. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
3. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
4. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
5. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
6. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
7. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
9. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
11. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Eurofins Genomics today announced the ... more customers to receive their primers in a shorter ... in quality found with other providers. Express oligos are ... at no additional fee. Researchers ... studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... an organic compound called fulvic acid that farms, greenhouses and hydroponics operations use ... cannabis are among the fastest growing segments of customers using this high grade ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... Oregon and Pune, India , January 12, 2017 /PRNewswire/ ... vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis and ... $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR of ... ... Allied Market Research Logo ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):